Qiagen sales, earnings climb in Q3

By The Science Advisory Board staff writers

October 14, 2020 -- Significant ongoing demand for COVID-19 testing and improved trends in other areas of Qiagen's product portfolio led to a 26% increase in preliminary net sales for the company during its third quarter.

For the period (end-September 30), Qiagen expects to report net sales of $481.3 million, up 26% at both actual and constant exchange rates from the $382.7 million produced in the third quarter of 2019. Non-COVID-19 testing products declined at only a mid-single-digit rate compared with the same period a year ago.

Qiagen said that preliminary adjusted earnings per share (EPS) are approximately $0.58 at constant exchange rates, up from adjusted EPS of $0.36 in the third quarter of 2019. Full results will be reported on November 4.

Qiagen expands genomic tools for COVID-19 research
Qiagen launched a SARS-CoV-2 primer panel that converts viral RNA samples into libraries that are ready for next-generation sequencing of the novel coronavirus...
Thermo Fisher's acquisition of Qiagen falls short
Thermo Fisher Scientific has terminated its acquisition of Qiagen after the company was unable to secure the number of shares needed to proceed with the...

Copyright © 2020 scienceboard.net

CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter